Shanghai Pharmaceutical Group Co. Ltd.

Company Snapshot

Founded: 1994
Entity Type: Public
Employees: 49,608
Region: China
Revenue: $39,447.6 Millions
Revenue Year: 2025
Headquarter: Shanghai, China
Key Geographics: China, Hong Kong
Corporate Address: Shanghai Pharmaceutical Building, 200 Taicang Road, Shanghai 200020 China Tel. +1-86-216-3730-908 www.sphchina.com

Company Overview

Founded in 1994 and headquartered in Shanghai, China, Shanghai Pharmaceuticals Holding is a global pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products. The company commercializes more than 700 drug varieties of drugs on a global basis, covering more than 20,000 healthcare institutions in different parts of the world.

Shanghai Pharmaceuticals promotes the fundamental beliefs of “development, integrity, cooperation, inclusion, responsibility,” and it is committed to improving the health and quality of life of individuals through the manufacturing and supply of better therapeutics than are currently available. The company is committed to providing effective therapeutic medicines for anticancer and immunoregulation, including cardiovascular system, serious chronic disease, metabolism and anti-infection. Its key products include Feng Tingxin, Nuoxin Kang and Hydroxychloroquine sulfate tablets.

Shanghai Pharmaceutical’s R&D area aims the company’s efforts toward making high-quality drugs. Four of its products that have successfully passed consistency evaluation are: fluoxetine hydrochloride capsules, metformin hydrochloride sustained-release tablets, hydrochlorothiazide tablets and captopril tablets. Shanghai Pharmaceuticals has more than 32 products whose specifications completed the BioEquivalency (BE) test and were submitted to the National Medical Products Administration (NMPA) in 2021. These include levonorgestrel tablets, ibuprofen sustained-release capsules and duloxetine hydrochloride enteric-coated capsules. Using mature hematoma CAR-T, the company engages in cellular therapy research on solid tumor CAR-T at the SPH Biotherapeutics Center.

Shanghai Pharmaceuticals has expanded its R&D ventures in consistency assessments to completely exploit the newly regulated market and to provide affordable pharmaceutical options to patients.

Financial Highlights (FY 2025)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Shanghai Pharmaceutical Group Co. Ltd. In Reports

Best Selling Pharmaceutical Drugs in 2021

BCC Research Market Analysis Report for Best Selling Pharmaceutical Drugs in 2021. Pharmaceutical Drugs market can grow from $1.3 tln to $1.8 tln in 2027.

Global Pharmaceutical Drugs Industry: Competitive Landscape 2021

BCC Research Market Report for Pharmaceutical Drugs Industry Competitive Landscape of top 50 Pharmaceutical manufacturers in the global market.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

BCC Research Market Report for Chronic Disease Management. Global Chronic Disease Management market trends, with CAGRs through 2026.

Company's Business Segments

  • Main Operating Activities : This segment includes R&D Innovation, Lean Manufacturing, Distribution Services, Retail Services, Field expansion
  • Other Operating Activities : This segment includes Finance income, Other sources of Income.

Applications/End User Industries

  • Pharmaceutical
  • Healthcare
  • Innovative Drug
  • Nephropathy
  • Myasthenia
  • Pemphigus
  • Clinical Applications
  • Psychiatric
  • Cardiovascular
  • Neurological
  • Life Sciences
AI Sentiment